Investing.com - Arcus Biosciences reported on Monday third quarter earnings that beat analysts' forecasts and revenue that topped expectations.
Arcus Biosciences announced earnings per share of $-0.90 on revenue of $33.58M. Analysts polled by Investing.com EPS of $-1.05 on revenue of $21.86M.
Arcus Biosciences 's are down 39.79% and is trading at $24.36 , still down 50.39% from its 52 week high of $49.10 set on Monday, November 22, 2021.
Arcus Biosciences follows other major Healthcare sector earnings this month
Arcus Biosciences's report follows an earnings beat by UnitedHealth on Friday, October 14, 2022, who reported EPS of $5.79 on revenue of $80.9B, EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on Tuesday, October 18, 2022 with third quarter EPS of $2.55 on revenue of $23.79B, for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar